Revelation Biosciences, Inc.
REVB
$1.24
-$0.02-1.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 57.56% | -10.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.35% | -21.05% | |||
| Operating Income | -32.35% | 21.05% | |||
| Income Before Tax | -31.66% | 21.98% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -31.66% | 21.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -31.66% | 21.98% | |||
| EBIT | -32.35% | 21.05% | |||
| EBITDA | -32.51% | 21.10% | |||
| EPS Basic | 76.71% | 74.77% | |||
| Normalized Basic EPS | 42.88% | 76.32% | |||
| EPS Diluted | 76.71% | 74.77% | |||
| Normalized Diluted EPS | 42.88% | 76.32% | |||
| Average Basic Shares Outstanding | 130.49% | 229.45% | |||
| Average Diluted Shares Outstanding | 130.49% | 229.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||